StemLife is Malaysia’s first and leading life-science company in the stem cell industry with a mission to offer modern and advanced medical treatments for major diseases afflicting Malaysians.
StemLife recognised the need to establish and build a large base of banked stem cells, the process of which would also create and develop awareness of the uses of stem cells and establish the market for potential stem cell therapy users. Cellular and tissue regeneration, which only stem cells can provide, is known to be the path to natural and sustained healing, as current drug treatments or surgery may only be palliative.

Through our stem cell banking divisions, we continue to assist in development of stem cell therapies in Malaysia, to remain as the front-runner in Malaysia’s regenerative medicine market and the obvious choice to consult on stem cells.

StemLife has been successfully involved in the treatments of patients with various conditions. As at the latest practicable date, we have assisted in over 200 successful applications (both allogenic and autologous) for leukemia, lymphoma, thalassaemia major, heart disease, diabetic foot ulcers and cartilage knee injuries.

All patients with thalassaemia major remain transfusion-free 3 years after transplant. Patients with heart disease saw an improvement in the pumping efficiency of their heart after stem cell therapy. Stem cells were also found to heal foot ulcers in the patients with diabetes. We are progressively offering therapies for patients with joint cartilage injuries in the knee and other joints in the body. ThaiStemLife has also put autologous cord blood to use in 2 patients with cerebral palsy (brain injury), with no significant side-effects and both are gradually showing signs of improvement.

Declared as an MSC status company, and now a BioNexus Status company under Biotech Corp Malaysia, StemLife possesses vision of promoting regenerative medicine in the form of stem cell therapy to Malaysians, and elevate Malaysia as the leading stem cell therapeutic treatment centre in South East Asia. With advancements being made in stem cell therapies, the Company aims to provide stem cell banking, stem cell therapies and consultancy services to the Malaysian public at an affordable cost as compared to procuring these services overseas.

Our principle activities are:

• Stem cell therapies and consultancy services
  
• Collection, testing, processing and cryopreservation of cord blood stem cells
  
• Harvesting, testing, processing and cryopreservation of peripheral blood stem cells.
  
• Investment holding
  

Year	Milestones
2001	Incorporation of StemLife Berhad
2002	1st cord blood stem cell unit collected, processed and stored
2003	Expanded nationwide Expanded to East Malaysia Co-founded APCBBC
2004	1st withdrawal of cord blood stem cell unit by client, (for treatment of leukemia) Turnover and Profit achieved
2005	2nd withdrawal of cord blood stem cell unit by client, (for treatment of thalassaemia major) Official launch of Peripheral Blood Stem Cell (PBSC) service 1st PBSC sample harvested, processed, tested and stored. Incorporation of ThaiStemLife
2006	Achieved public-listing on MESDAQ stock exchange: StemLife Berhad Initiation of research and development with National University of Singapore for stem cell expansion and nanotechnology Initiated animal research for cartilage regeneration Winner of the Technology Business Review Award for excellence in Biotechnology Winner of Deloitte Technology Fast 500 Asia Pacific Award 2006
2007	3rd withdrawal of cord blood stem cell unit by client (for treatment of leukemia) Launch of 3 novel services with special guest and cord blood client Sheila Majid: StemGuard, StemAssured, Stem21 Granted Bionexus Status by BioTech Corp Chairman and Secretariat of the Asia Pacific Cord Blood Consortium (APCBBC), consisting of 8 leading member countries across the region Winner of Deloitte Technology Fast 500 Asia Pacific Award 2006, Panelist for Entrepreneur Forum Nominated for Ernst and Young Entrepreneur of the Year Award Launch of StemLife Logistics, with our own fleet of vehicles to provide end-to-end comprehensive logistics service for our products Launched knee cartilage regeneration pilot study and clinical trials
2008	Officially licensed under the Private Healthcare Facilities and Services Act 1998, under Ministry of Health 4th cord blood stem cell withdrawal (for Thalassemia major) Full organization (HQ and nationwide branches) Certified ISO 9001:2000 Winner of BioInno Award for new innovations at BioMalaysia 2008 Special Briefing and Update to Minister of Health on stem cell applications Inaugural StemLife Regenerative Lecture featuring Professor Dr. Colin McGuckin, leading scientific researcher, UK Launch of StemShield (new benefit service for clients) Launch of Automated Processing systems AXP AutoXpress Processing
2009	Launch of StemCourier Launch of StemShieldPLUS (now also inclusive for matched cord blood units) Total of almost 30,000 cord blood banking clients

^ Back to Top